Introduction
============

Radiotherapy (RT) is a main modality for anticancer treatment. Radiation directly ionizes atoms of the cancer cells and makes excited electrons. These secondary electrons directly damage the DNA of cancer cells. The electrons also make free radicals by interacting with water in the tissue, which can damage the DNA of cancer cells. This is the indirect action of radiation. Incomplete repair of these damaged DNA causes several modes of cell death, such as apoptosis, autophagy, or senescence. Radiosensitivity varies according to cells, tissues, and organs. In particular, lymphocytes show high radiosensitivity even in a low dose, so RT has been used as an immunosuppressive therapy, such as total body irradiation for conditioning prior to bone marrow transplantation. Also, RT can activate immunosuppressive transforming growth factor-β (TGF-β) and tumor promoting macrophage \[[@b1-roj-2016-02033]\]. However, RT can induce immunologic cell death providing tumor specific peptides presented by major histocompatibility complex (MHC) class I of antigen-presenting cells (APCs) and recognized by cytotoxic T cells \[[@b2-roj-2016-02033]\]. Furthermore, RT also can activate APCs possessing anti-tumor immunity \[[@b3-roj-2016-02033]\]. These T cells infiltrate to the tumor site, secrete interferon γ (IFN-γ), and kill tumor cells \[[@b4-roj-2016-02033]\]. Specific combination of signals could be released either, which stimulate tumor-specific cytotoxic T lymphocytes even in the distant sites, so-called "abscopal effect." The systemic effects induced by local RT have been reported in patients with several types of solid tumors, such as melanoma, renal cell carcinoma, and lung adenocarcinoma \[[@b5-roj-2016-02033]\] ([Table 1](#t1-roj-2016-02033){ref-type="table"}).

Immune Checkpoint Blockades
===========================

Immune checkpoint blockades have been showing remarkable progress in the field of immunotherapy, regulating key immunosuppressive pathways of cancer cells. Targets of checkpoint blockades are cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1), crucial molecules for peripheral CD8+ T cell tolerance induced by APC. CTLA-4, a trans-membrane protein receptor which expressed in T cells, affects priming phase of immune response. It is transported to the surface when T cell receptor (TCR) recognizes an antigenic peptide in association with MHC of APC. For the complete T cell stimulation, CD28 receptor of T cell and B7 ligand of APC are needed to be bound for a co-stimulatory pathway \[[@b6-roj-2016-02033]\]. CTLA-4 has higher affinity, thus inhibits proliferation of T cells by outcompeting CD28 receptor for ligand binding. CTLA-4 mediated T cell immune tolerance also can be achieved by production of cytokines such as TGF-β in regulatory T cells \[[@b7-roj-2016-02033]\]. Another key inhibitory receptor PD-1 is on surface of T cell and B cell, and binds to programmed death-ligands 1 and 2 (PD-L1 and PD-L2). PD-L1 is widely expressed on hematopoietic and non-hematopoietic cells. The main role of PD-1/PD-L1 system is to limit the response of effecter T cell and the immunemediated damage of tissues. PD-L1 is also expressed on various types of solid tumors and hematologic malignancies. Tumor cells with PD-L1 expression can escape from T cell related immune reaction, and this adaptive resistance is regulated by cytokines, such as tumor necrosis factor-α (TNF-α) and IFN-γ \[[@b8-roj-2016-02033]\].

In clinical trials using the checkpoint blockades, anti-CTLA-4 and anti-PD-1 monoclonal antibodies (mAbs), improved survival outcomes were reported for patients with advanced solid tumors, in particular melanoma and non-small cell lung cancer (NSCLC). Ipilimumab, an anti-CTLA-4 mAb, was administered for metastatic melanoma. Response rate was 11% to 15.2% and median overall survival (OS) time was 10.1 to 11.2 months. Adverse effect rate was higher, grade 3 to 4 events occurred in 45% to 60% of patients. Of these, immune-related adverse effects were 10% to 41.7%. Common side effects were skin reaction, diarrhea, and increased liver enzyme \[[@b9-roj-2016-02033],[@b10-roj-2016-02033]\]. Interestingly, survival benefit was lasted for long time, a plateau was found after 3-year, and OS rate was 18.2% at 5-year \[[@b11-roj-2016-02033]\]. Anti-PD-1 mAbs (nivolumab and pembrolizumab), comparing with ipilimumab, were reported to prolong survival and response rate, while decrease adverse effect in metastatic melanoma patients \[[@b12-roj-2016-02033],[@b13-roj-2016-02033]\]. In the trial using pembrolizumab (vs. ipilimumab), 1-year OS rate was 68.4%--74.1% (vs. 58.2%), response rate was 32.9%--33.7% (vs. 11.9%), and grade 3 to 5 adverse effect rate was 10.1% to 13.3% (vs. 19.9%) \[[@b13-roj-2016-02033]\].

In the patients with chemo-refractory NSCLC, nivolumab showed better treatment outcomes than docetaxel. Median OS was 9.2--12.2 vs. 6.0--9.4 months and response rate was 19%--20% vs. 9%--12%. Grade 3 to 4 adverse events were less in nivolumab group, 7%--10% vs. 54%--55%. Of these patients having response to nivolumab, response duration time was very long, median time was 17.2 months or unreached \[[@b14-roj-2016-02033],[@b15-roj-2016-02033]\]. Pembrolizumab also compared with docetaxel in PD-L1-positive NSCLC patients who had history of treatment. Median OS was 10.4--12.7 months vs. 8.5 months, and response rate was 18.0%--18.5% vs. 9.3%. Patients with PD-L1 positive in 50% or more tumor cells had more improved outcomes, median OS was 14.9--17.3 months vs. 8.2 months, and response rate was 29.1%--30.2% vs. 7.9%. Grade 3-5 treatment-related toxicity rate was lower with pembrolizumab, 13%--16% vs. 35% \[[@b16-roj-2016-02033]\].

Checkpoint blockades have shown improved treatment outcomes in the clinical trials for advanced melanoma and NSCLC patients with previous systemic treatments. Notably, the response rate of pembrolizumab was not significantly lower even in the patients with ipilimumab history \[[@b17-roj-2016-02033],[@b18-roj-2016-02033]\]. Nonetheless, advanced solid tumors other than melanoma or NSCLC have not been reported to have considerable efficacy or safety of checkpoint blockades \[[@b19-roj-2016-02033],[@b20-roj-2016-02033]\]. Hence, combination strategies are actively discovered to extend the target of checkpoint blockades, using chemotherapy or small molecules. RT is also a promising partner of checkpoint blockades in terms of the immunogenic effect as mentioned above.

RT Combined with Checkpoint Blockades: Preclinical Data
=======================================================

Regulatory T (Treg) cells are more radioresistant than other T cells, consequently increased by RT \[[@b21-roj-2016-02033]\]. Naturally, an important role of Treg cells is to maintain immune tolerance, even in tumorous condition. CTLA-4 is reported to be a key target to control the suppressive function of Treg cell \[[@b22-roj-2016-02033]\]. Thus, the combination of RT and anti-CTLA-4 mAb has been investigated to overcome tumor immunity. Demaria et al. \[[@b23-roj-2016-02033]\] injected poorly immunogenic 4T1 metastatic mouse mammary carcinoma cells into mice, and then performed 2 by 2 arms of treatment: (RT or no-RT) × (CTLA-4 mAb or control immunoglobulin G \[IgG\]). When RT was combined with anti-CTLA-4 mAb, the survival was significantly extended and lung metastasis was controlled. In this study, CD8+ T cell was shown to have crucial role, while CD4+ T cell did not. Antitumor immunity was also confirmed in other types of cell lines, such as mesothelioma \[[@b24-roj-2016-02033]\] and glioma \[[@b25-roj-2016-02033]\].

Though the combination of RT and anti-CTLA-4 mAb has been reported to have improved response, the unresponders are more common than the responders. In this point of view, the importance of PD-L1/PD-1 co-inhibitory pathway has been noted, which modulate microenvironment to facilitate activation of CD8+ T cells \[[@b26-roj-2016-02033]\]. Twyman-Saint Victor et al. \[[@b27-roj-2016-02033]\] obtained resistant murine melanoma cells from mice with relapsed tumor after the combination of RT and anti-CTLA4 mAb. The authors found that the resistance was associated with the exhaustion of CD8+ T cell and the upregulation of PD-L1 by cancer cells. After the addition of anti-PD-L1 mAb, exhausted CD8+ T cell was reversed and the response was improved. In addition to effector T cells, down-regulation of tumor-infiltrating myeloid-derived suppressor cells by TNF-α was reported to be associated with antitumor immunity \[[@b28-roj-2016-02033]\], and blocking of TGF-β might be a another strategy \[[@b29-roj-2016-02033]\]. Thus, murine melanoma cell line was a preceding model to confirm the effect of the combination of anti-PD-1/PD-L1 mAb and RT \[[@b30-roj-2016-02033]\]. Actually, improved anti-tumor immunity has been revealed in breast \[[@b28-roj-2016-02033]\], colon \[[@b31-roj-2016-02033]\], and renal cell carcinoma \[[@b32-roj-2016-02033]\].

Furthermore, impressive feature of immunotherapy, immune memory was confirmed. Zeng et al. \[[@b33-roj-2016-02033]\] selected "cured mice," which survived more than 90 days after the combined treatment of RT and anti-PD-1 mAb for murine glioma, and injected same cell line. At the same time, naive mice were injected with same cell line. All of naive mice had \>1 cm^3^ tumors after 21 days of implantation, while none of cured mice had tumors after 60 days of implantation. Enhanced abscopal effect was also been reported in other study, combined treatment of RT and anti-PD-1 mAb significantly inhibited the growth of secondary unirradiated tumors, comparing with single treatment of RT or anti-PD-1 mAb \[[@b32-roj-2016-02033]\] ([Table 1](#t1-roj-2016-02033){ref-type="table"}).

RT Combined with Checkpoint Blockades: Clinical Data
====================================================

At this time, a limited number of clinical trials reported results of combined RT and checkpoint blockades, moreover, most of them used anti-CTLA-4 mAb. A phase I/II study for patients with metastatic castration-resistant prostate cancer evaluated safety and efficacy of ipilimumab, an anti-CTLA-4 mAb with or without radiotherapy. RT was delivered to metastatic bone lesion with 8 Gy single fraction 1 to 2 days before the first ipilimumab. The dose of ipilimumab was escalated as 3, 5 or 10 mg/kg without RT, or 3 or 10 mg/kg with RT. Response was assessed after up to 4 cycles (3 weeks per cycle). Among 34 patients with 10 mg/kg ipilimumab and RT, grade 3 to 4 immune-related adverse effects occurred in 18% of patients (colitis, 6%; hepatitis, 6%; and diarrhea, 6%), and ≥50% prostate-specific antigen (PSA) decline was confirmed in 12% of patients \[[@b34-roj-2016-02033]\]. In a phase III trial, ipilimumab was compared with placebo for metastatic castration-resistant prostate cancer patients. Single fraction RT (8 Gy) was given for metastatic bone lesion within the 2 days before the medication. Ipilimumab (10 mg/kg) or placebo was administered every 3 weeks for up to 4 cycles, and continued every 3 months until disease progression or severe toxicity. A total of 799 patients were randomly assigned to ipilimumab (n = 399) and placebo (n = 400) groups. Though OS for the entire patients was not increased with ipilimumab (11.2 vs. 10.0 months, p = 0.053), progression-free survival (4.0 vs. 3.1 months, p \< 0.0001) and ≥50% PSA decline (13.1% vs. 5.2%) was improved. Grade 3 to 4 immune related adverse effects were noted in 26% of ipilimumab group and 3% of placebo group, and common immune related events were diarrhea (15% vs. \<1%) and colitis (5% vs. 0%). Four patients (1%) in ipilimumab group had ipilimumab-related death \[[@b35-roj-2016-02033]\]. These two clinical trials reported similar rate of severe immune-related toxicity comparing with aforementioned phase III immunotherapy trials without RT, hence we can expect the combination of RT and checkpoint blockades could be a useful treatment modality. More data can be found in retrospective studies, and they may give us additional clue to identify the benefit of the combination.

In the real world, immunotherapy is usually tried for patients with systemic metastasis, thus RT may be particularly used as palliative intent. As expected, palliative RT (median dose of 30 Gy) combined with ipilimumab (median dose of 10 mg/kg) was reported to have appropriate palliative effect without significant increase of immune-related adverse effects \[[@b36-roj-2016-02033]\]. If the abscopal effect is confirmed in clinical data, the combination of RT and immunotherapy can be more useful. Several case reports have observed the abscopal effect of local RT. A metastatic melanoma patient who had showed stable disease with ipilimumab received palliative RT (28.5 Gy in 3 fractions) when the disease progressed. Shortly after RT, there was not a response. However, a significant regression was observed in both of irradiated lesion and distant non-irradiated lesions after an additional dose of ipilimumab \[[@b37-roj-2016-02033]\]. In another case report, a patient with metastatic lung adenocarcinoma underwent palliative RT (30 Gy in 5 fractions) concomitantly with ipilimumab. After the concomitant treatment, significant reduction of tumor size and metabolic uptake was detected in whole body, furthermore, the carcinoembryonic antigen level was normalized either \[[@b38-roj-2016-02033]\].

Brain metastasis can be a typical model of combined treatment of RT and immunotherapy, since complete resection is difficult and systemic agents hardly penetrate the blood--brain barrier. Survival benefit of the combination of brain RT and ipilimumab was reported in a study for brain metastatic melanoma patients, the combined treatment showed better OS (median, 21.3 vs. 4.9 months; p = 0.044) than radiosurgery alone \[[@b39-roj-2016-02033]\]. The abscopal effect observed either. A retrospective study reported treatment results of 13 patients with brain metastatic melanoma who treated with ipilimumab (3 mg/kg) and whole-brain RT (WBRT; median 30 Gy in 10 fractions) within 30 days of one another. Extracranial response rate was evaluated in 10 patients, and the response rate was 20% (complete response 1, partial response 1, and stable disease 2). The rate of grade 3 to 4 central nervous system-related acute toxicity was low, reported in only 1 patient. Notably, all patients who had post-WBRT imaging had new or worsened intratumoral hemorrhage (median, 53 days) \[[@b40-roj-2016-02033]\]. However, the influence of RT or ipilimumab on hemorrhage should be cautiously considered, because intratumoral hemorrhage is commonly occurred in melanoma metastases. Actually, in another study for brain metastatic melanoma patients, more intratumoral hemorrhage was occurred in brain RT alone group than brain RT and ipilimumab group (12.5% vs. 3.9%) \[[@b41-roj-2016-02033]\].

In summary, clinical data for the combination of RT and checkpoint blockades are still scanty and concentrated on a certain agent, ipilimumab. Nonetheless, based on the results of several retrospective studies, we can expect that the combined treatment may be synergistic without significant increase of immune-related adverse effects.

How to Combine RT with Checkpoint Blockades?
============================================

Several technical issues should be considered for combination of immune checkpoint and RT, such as fractionation schedule and sequence of RT. We should look back on preclinical data to find appropriate fraction size. In a mouse model using B16 melanoma cells, 20 Gy was delivered in 1 fraction or 5 fractions. Increased reduction of primary tumor or distant metastasis was reported in single fractionation group rather than fractionation group. This ablative RT-initiated immunity was CD8+ T-cell dependent \[[@b42-roj-2016-02033]\]. In other study using a fractionated schedule of RT (2 Gy × 5), upregulation of PD-L1 was observed in murine colon carcinoma cells of mice \[[@b43-roj-2016-02033]\]. This is the adaptive immune-evading mechanism of tumor cells, depending on IFN-γ produced by CD8 T cell. In contrast, single fraction RT with higher dose (10 Gy) decreased the expression of PD-L1 in human prostate cancer cell lines in vitro \[[@b44-roj-2016-02033]\].

Based on these results, ablative RT with single fraction might be suggested to initiate immunologic response better than fractionated RT. However, 2 to 5 Gy per fraction which used in aforementioned studies is a relatively conventional schedule. Fractionated RT with conventional low daily dose may be less immunologic, at least in the setting of metastatic disease. Silk et al. \[[@b41-roj-2016-02033]\] reported that survival benefit of ipilimumab was confirmed in radiosurgery group (19.9 vs. 4.0 months; p = 0.009), while not in WBRT (3.1 vs. 5.3 months; p = 0.60). In this study, RT dose was 30--37.5 Gy in 10--13 fractions and 14--24 Gy in 1--5 fractions for radiosurgery. Therefore, fractionated RT with higher daily dose should be compared with single fraction RT. Actually, Dewan et al. \[[@b45-roj-2016-02033]\] injected TSA mouse breast carcinoma or MCA38 mouse colon carcinoma cells into the both flanks of mouse. RT was given to "primary site" as 20 Gy in single fraction, 8 Gy in 3 fractions, and 6 Gy in 5 fractions. 9H10 monoclonal antibody against CTLA-4 was combination with RT or not. Interestingly, the RT regimen with 8 Gy × 3 fractions showed most enhanced response regardless of tumor sites.

Regarding the sequence of RT and immunotherapy, it is another uncertainty. In one study for brain metastatic melanoma, response rate was 40% in RT after ipilimumab and 16.7% in RT before ipilimumab \[[@b41-roj-2016-02033]\]. On the contrary, in other study for melanoma brain metastases, patients underwent radiosurgery during or before ipilimumab had better OS than those underwent radiosurgery after ipilimumab (at 1 year, 65% vs. 56% vs. 40%, p = 0.008). However, patients underwent radiosurgery during ipilimumab showed more frequent central nervous system toxicities, for example, hemorrhage was found in 40%, compared with 18% in patients underwent radiosurgery before or after ipilimumab \[[@b46-roj-2016-02033]\]. However, small number of patients and retrospective nature is the limitations of these studies to clarify the optimal sequence of RT and immunotherapy.

Ongoing Trials and Future Perspectives
======================================

Major issues for the combined treatment of RT and checkpoint blockades can be summarized as follows. Above all, more types of cancer, beyond melanoma and NSCLC, must be considered as the indication of combined treatment. Especially, several cancers with poor prognosis or limited applicable systemic agents, such as pancreas and triple negative breast cancers, were reported to be possibly immunogenic \[[@b47-roj-2016-02033],[@b48-roj-2016-02033]\], so multiple studies have been conducted for varied types of cancer ([Table 2](#t2-roj-2016-02033){ref-type="table"}). Additionally, anti-PD-1/L1 mAb, besides anti-CTLA-4 mAb, should be verified to have synergistic effect by the combined RT and immunotherapy. Most of preclinical and clinical studies used anti-CTLA-4 mAb, especially ipilimumab, being developed earlier than other agents. Tumor tissue studies in patients receiving neoadjuvant chemo-radiotherapy reported that PD-L1 expression was increased in tumor cells, but its influence on prognosis is very conflicting \[[@b49-roj-2016-02033],[@b50-roj-2016-02033]\]. Lastly, optimal combination schedule of RT and checkpoint blockades also has to be clarified, including fractionation schedule and sequence of RT and checkpoint blockades. Although RT with higher daily dose appears more immunogenic than RT with conventional daily dose in several preclinical or retrospective studies, we should take into account that the studies used RT in a palliative setting. For curative intent, conventionally fractionated (around 2 Gy per day) RT is still the mainstay, concerning possible normal tissue toxicity owing to usually combined systemic agents. Consequently, conventionally fractionated RT should be investigated in clinical trials whether has synergistic immunogenic effect, as well as the sequence of RT and immune checkpoint blockade. Selected ongoing trials are summarized in [Table 2](#t2-roj-2016-02033){ref-type="table"}.

Conclusion
==========

Immune checkpoint blockades have been emerged as promising anticancer therapy, showing enormous progression on clinical application. Pro-immune effect of RT is expected to boost efficacy of checkpoint blockades without significant increase of immune-related adverse event. Although the evidence of combined treatment is not sufficient yet, preclinical data suggest a potential benefit of combined RT and checkpoint blockades. Based on ongoing clinical trials, the latitude for clinical application of RT would be extended, from palliation to radical treatment modality, in the field of immunotherapy.
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###### 

Checkpoint blockades and effect of radiotherapy

  Ligands on tumor cell                                                                       Receptors on T cell                                             Ligands on antigen-presenting cell   Checkpoint blockade
  ------------------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------ -------------------------------------------------------
  PD-L1 and L2                                                                                PD-1                                                            \-                                   Anti-PD-1/L1 (atezolizumab, nivolumab, pembrolizumab)
  CTLA-4                                                                                      B7 (CD80, CD86)                                                 Anti-CTLA-4 (ipilimumab)             
  Effect of radiotherapy                                                                      To increase antigen presentation and CD8+ T cell infiltration                                        
  To stimulate tumor-specific cytotoxic T lymphocytes in the distant sites: abscopal effect                                                                                                        

PD-L1 and L2, programmed death-ligand 1 and ligand 2; PD-1, programmed death-1; CTLA-4, cytotoxic T-lymphocyte--associated protein 4.

###### 

Selected ongoing trials

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial no.     Phase   n     Condition                                                                              Intervention                                                  Sequence                                                      Radiotherapy schedule                                                                        Institute
  ------------- ------- ----- -------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------------- ----------------------------------------------------------
  NCT02406183   I       21    Metastatic melanoma                                                                    Ipilimumab + SBRT                                             Ipilimumab → RT (at day 39, 41, 43)                           SBRT 24, 30 or 36 Gy in 3 fractions                                                          Radiotherapie, University Hospital Ghent

  NCT02821182   II      40    Metastatic melanoma                                                                    Anti-PD-1 + SBRT                                              Concomitant                                                   24 Gy in 3 fractions (separated 2-3 days)                                                    University Hospital Ghent

  NCT02115139   II      66    Melanoma and brain metastases                                                          Ipilimumab + WBRT                                             Ipilimumab → WBRT (between cycle 1 day 2 and cycle 2 day 1)   30 Gy in 10 fractions                                                                        Grupo Espanol Multidis-ciplinar de Melanoma

  NCT02407171   I/II    60    Metastatic melanoma or non-small cell lung cancer                                      MK-3475 + SBRT                                                Concomitant                                                   30 Gy in 3 or 5 fractions                                                                    Yale University

  NCT02866747   I/II    62    Recurrent glioblastoma                                                                 HFRT\                                                         RT → durvalumab (on day 5 of RT)                              24 Gy in 3 fractions (days 1, 3, and 5)                                                      Institut Claudius Regaud
                                                                                                                     Durvalumab + HFRT                                                                                                                                                                                                        

  NCT02617589   III     550   Glioblastoma                                                                           Nivolumab + RT\                                                                                                             Bristol-Myers Squibb                                                                         
                                                                                                                     Temozolomide + RT                                                                                                                                                                                                        

  NCT01935921   I       18    Stage lll-IVB head and neck cancer                                                     Cetuximab + RT + ipilimumab                                   Cetuximab + RT → Ipilimumab (at week 4)                       66-70 Gy for 7 weeks                                                                         National Cancer Institute

  NCT02764593   I       120   Advanced head and neck squamous cell carcinoma                                         Nivolumab + cisplatin\                                        Nivolumab → (after 14 days) RT                                70 Gy in 35 fractions                                                                        RTOG
                                                                                                                     Nivolumab + cetuximab\                                                                                                                                                                                                   
                                                                                                                     Nivolumab + RT                                                                                                                                                                                                           

  NCT02759575   l/ll    47    Locally advanced laryngeal squamous cell carcinoma                                     Pembrolizumab + cisplatin + RT                                Concomitant                                                   70 Gy in 35 fractions                                                                        Nooshin Hashemi-Sa-draei

  NCT02609503   II      29    Locally advanced squamous cell carcinoma of the head and neck                          Pembrolizumab + IMRT                                          Concomitant                                                   7 weeks                                                                                      UNC Lineberger Comprehensive Cancer Center

  NCT02777385   II      44    Head and neck squamous cell carcinoma                                                  Pembrolizumab + cisplatin + IMRT                              CCRT → (3 weeks after) pembrolizumab\                         35 fractions                                                                                 University of Pittsburgh
                                                                                                                                                                                   Pembrolizumab → (1 week after) CCRT                                                                                                                        

  NCT02289209   II      48    Inoperable recurrence or second primary squamous cell carcinoma of the head and neck   Reirradiation + MK-3475                                       Concomitant                                                   1.2 Gy BID for 5 days weekly                                                                 Dan Zandberg, University of Maryland

  NCT02642809   0       15    Metastatic esophageal cancers                                                          Brachytherapy + pembrolizumab                                 Brachytherapy → pembrolizumab (within 1 week)                 16 Gy in 2 fractions                                                                         Washington University School of Medicine

  NCT02844075   II      28    Esophageal squamous cell carcinoma                                                     Neoadjuvant CCRT with taxol, carboplatin, and pembrolizumab   Concomitant                                                   44.1 Gy in 21 fractions                                                                      Yonsei University

  NCT02621398           30    Stage ll-IIIB non-small cell lung cancer                                               Paclitaxel + carboplatin + RT + pembrolizumab                 Concomitant                                                   5 Days a week for 6 weeks                                                                    Rutgers, The State University of New Jersey

  NCT02221739   II      39    Metastatic non-small cell lung cancer                                                  Ipilimumab + local RT                                         RT → ipilimumab (within 24 hours)                             6 Gy x 5 fractions 9.5 Gy x 3 fractions                                                      New York University School of Medicine

  NCT02525757   II      40    Non-small cell lung cancer                                                             CCRT with carboplatin and paclitaxel + MPDL3280A              Concomitant MPDL3280A → CCRT                                  60-66 Gy in 30-33 fractions                                                                  MD Anderson Cancer Center

  NCT02888743   II      180   Metastatic colorectal or non-small cell lung cancer                                    Tremelimumab + durvalumab\                                    Immunotherapy → RT (at week 2)                                Arm B:over 10 days for up to 3 fractions Arm C: every 6 hours BID on weeks 2, 6, 10 and 14   National Cancer Institute
                                                                                                                     Tremelimumab + durvalumab + high dose RT\                                                                                                                                                                                
                                                                                                                     Tremelimumab + durvalumab + low dose RT                                                                                                                                                                                  

  NCT02768558   III     660   Stage III unresectable non-small cell lung cancer                                      RT + cisplatin + etoposide +/-nivolumab                       CCRT → nivolumab                                              60 Gy                                                                                        RTOG

  NCT02303366   I       15    Oligometastatie breast cancer                                                          MK-3475 + SBRT                                                SBRT → MK-3475                                                20 Gy in 1 fraction                                                                          Peter MaeCallum Cancer Centre

  NCT02730130   II      17    Metastatic triple negative breast cancer                                               Pembrolizumab + RT                                            RT → pembrolizumab (at day 2)                                 30 Gy in 5 fractions                                                                         Memorial Sloan Kettering Cancer Center

  NCT01853618   I       100   Liver cancer                                                                           TACE or REA once only\                                        Tremelimumab → SBRT (at day 36)                               1 fraction                                                                                   National Cancer Institute
                                                                                                                     Repeat TACE\                                                                                                                                                                                                             
                                                                                                                     Tremelimumab + SBRT\                                                                                                                                                                                                     
                                                                                                                     Tremelimumab + cryoablation\                                                                                                                                                                                             
                                                                                                                     Tremelimumab + RFA                                                                                                                                                                                                       

  NCT02837263   I       15    Liver metastatic colorectal cancer                                                     SBRT + pembrolizumab                                          SBRT → pembrolizumab                                          40-60 Gy in 5 fractions                                                                      University of Wisconsin, Madison

  NCT02298946   I       17    Metastatic colorectal cancer                                                           Cyclophosphamide + SBRT + AMP-224                             SBRT (days -2, -1, 0 or day 0) → medication                   8 Gy x 1 or 3 fractions                                                                      National Cancer Institute

  NCT02948348   l/ll    50    Rectal cancer                                                                          Preoperative CCRT with capecitabine + nivolumab               Concomitant                                                   45 Gy in 25 fractions                                                                        Takayuki Yoshino, National Cancer Center Hospital East

  NCT02868632   I       36    Unresectable, non-met-astatic pancreatic cancer                                        MEDI4736+ SBRT\                                               SBRT → immunotherapy (within 4 hours)                         6 Gy x 5 fractions                                                                           New York University School of Medicine
                                                                                                                     Tremelimumab + SBRT\                                                                                                                                                                                                     
                                                                                                                     MEDI4736 + tremelimumab + SBRT                                                                                                                                                                                           

  NCT02311361   I       60    Unresectable pancreatic cancer                                                         MEDI4736 + SBRT\                                                                                                                                                                                                         National Cancer Institute
                                                                                                                     Tremelimumab + SBRT\                                                                                                                                                                                                     
                                                                                                                     MEDI4736 + tremelimumab + SBRT                                                                                                                                                                                           

  NCT02648282   II      54    Locally advanced pancreatic cancer                                                     Cyclophosphamide + pembrolizumab + GVAX + SBRT                Immunotherapy → SBRT (at second dose)                         6.6 Gy for 5 days (at 2nd cycle)                                                             Sidney Kimmel Comprehensive Cancer Center

  NCT02855203   I/II    30    Oligometastatic renal tumors                                                           Pembrolizumab + SBRT                                          SBRT → pembrolizumab                                          18-20 Gy x 1 fraction                                                                        Peter MaeCallum Cancer Centre, Australia

  NCT02599779   II      35    Stage IV renal cell cancer                                                             Pembrolizumab + SBRT                                          Pembrolizumab → SBRT                                                                                                                                       Sunnybrook Health Sciences Centre

  NCT02880345   \-      14    Advanced urothelial cancer                                                             Pembrolizumab + HFRT or SBRT                                                                                                8 Gy x 3 fractions 17 Gy x 1 fraction                                                        Abramson Cancer Center of the University of Pennsylvania

  NCT02891161   l/ll    42    Urothelial cancer (T2-4 NO-2 MO) of the bladder                                        Durvalumab + RT                                               Concomitant                                                   64.8 Gy in 36 fractions                                                                      Monika Joshi, Big Ten Cancer Research Consortium

  NCT02843165   II      146   Metastatic cancer                                                                      Anti-CTLA-4 or anti-PD-1/LI mAb +/-SBRT                       Concomitant                                                   9.5 Gy x 3 fractions (1-21 days)                                                             University of California, San Diego

  NCT01711515   I       28    Locally advanced cervical cancer                                                       Cisplatin + EBRT and brachytherapy + ipilimumab               Cisplatin + RT → ipilimumab (within 2 weeks)                                                                                                               National Cancer Institute
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Anti-CTLA-4 (ipilimumab, tremelimumab); Anti-PD-1/L1 (AMP-224, durvalumab, MEDI4736, MPDL3280A, MK-3475, nivolumab, pembrolizumab).

SBRT, stereotactic body radiotherapy; RT, radiotherapy; WBRT, whole brain radiotherapy; HFRT, hypofractionated radiotherapy; RTOG, Radiation Therapy Oncology Group; IMRT, intensity modulated radiotherapy; CCRT, concurrent chemo-radiotherapy; TACE, transcatheter arterial chemoembolization; RFA, radiofrequency ablation ; mAbs, monoclonal antibodies; EBRT, external beam radiation therapy.
